Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-adjuvant chemotherapy selection in operable breast cancer
ISRCTN15094808Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cyclophosphamide, fluorouracil, epirubicin and trastuzumab in breast cancer (2 arms), sponsored by University of Birmingham. Primary endpoint: Complete pathological response rate. Started Jul 2015; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN15094808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15094808.